-
公开(公告)号：WO2023091783A1
公开(公告)日：2023-05-25
申请号：PCT/US2022/050701
申请日：2022-11-22
发明人： KIM, Sungjune , HAMAIDI, Imene
IPC分类号： A61K35/17 , A61K31/165 , A61K31/192 , A61K31/341 , C12N15/113 , A61P3/00 , A61P7/00
摘要： Disclosed are methods of making engineered cells comprising reduced Sirt6 expression as well as the cells that are the products of said methods. Thus, in one aspect, disclosed herein are engineered lymphocytes comprising reduced Sirt6 expression. Also disclosed herein are methods of treating cancer in a subject that involves collecting lymphocytes, such as tumor infiltrating lymphocytes (TILs), from the subject, treating the lymphocytes ex vivo to inhibit Sirt6 expression, and transferring the modified lymphocytes to a subject with a cancer.
-
公开(公告)号：WO2022272259A1
公开(公告)日：2022-12-29
申请号：PCT/US2022/073079
申请日：2022-06-22
IPC分类号： C07K14/705 , C12Q1/6886
摘要： As disclosed herein, high expression of the inhibitory ligands Galectin-3 (LAG-3 ligand), Galectin-9 (Tim-3 ligand), HMGB1 (Tim-3 ligand), CD112 (CD112R ligand) and TNFSF10 (DR5 ligand) in the microenvironment of triple negative breast cancer cells is inhibitory for T-cells. Therefore, disclosed herein is a chimeric receptor comprising an extracellular domain of TIM-3, LAG-3, CD112R or DR5 and transmembrane and intracellular domain of a pro-inflammatory interleukin and/or a co-stimulatory domain. Also disclosed is an immune effector cell engineered to express a chimeric antigen receptor (CAR) polypeptide and the disclosed chimeric receptor. Also disclosed is a method of providing an anti-cancer immunity in a subject with a MUC1-expressing cancer, the method comprising administering to the subject an effective amount of the disclosed immune effector cell, thereby providing an anti-tumor immunity in the subject.
-
公开(公告)号：WO2022266418A1
公开(公告)日：2022-12-22
申请号：PCT/US2022/033947
申请日：2022-06-17
IPC分类号： C07D487/04 , C07D235/06 , A61K31/53
摘要： Disclosed are inhibitors for CDK12/13 and uses thereof. Methods of using the disclosed compounds to treat cancer are also disclosed.
-
公开(公告)号：WO2022236017A1
公开(公告)日：2022-11-10
申请号：PCT/US2022/028022
申请日：2022-05-06
发明人： LE-LAU, Eric K.
IPC分类号： A61P35/00 , A61K31/015 , A61K31/03 , A61K31/047 , A61K31/095 , A61K38/04
摘要： Disclosed are methods for treating, inhibiting, reducing, and/or preventing cancers (such as, for example melanoma) and/or metastasis (such as, for example metastatic melanoma) comprising administering to a subject a L-fucose and an anti-androgen therapy.
-
公开(公告)号：WO2022226284A1
公开(公告)日：2022-10-27
申请号：PCT/US2022/025910
申请日：2022-04-22
发明人： ANDERSON, Alexander R. A. , ROBERTSON-TESSI, Mark , GATENBEE, Chandler D. , PRABHAKARAN, Sandhya
摘要： A method of processing medical image data to predict disease progression in non-small cell lung cancer (NSCLC) patients includes receiving a multiplexed tissue image comprising a plurality of cells stained for one or more markers, evaluating the multiplexed tissue image using a machine learning model, and predicting whether a patient's NSCLC will progress based on the evaluation of the multiplexed tissue image using the machine learning model.
-
6.发明申请
公开(公告)号：WO2022225909A1
公开(公告)日：2022-10-27
申请号：PCT/US2022/025319
申请日：2022-04-19
发明人： JI, Haitao
IPC分类号： A61K31/445 , C07D211/44
摘要： Described herein are small molecule inhibitors of the β-catenin/B-cell lymphoma 9 interaction and pharmaceutical compositions including a therapeutically effective amount of the small molecule inhibitors described herein. Described are also methods of treating oncological disorders, for example cancer by administering the small molecule inhibitors of the β-catenin/B-cell lymphoma 9 interaction described herein.
-
公开(公告)号：WO2022187839A1
公开(公告)日：2022-09-09
申请号：PCT/US2022/070938
申请日：2022-03-03
发明人： CHEN, Jiandong
摘要： Disclosed herein is a method for treating a tumor having a temperature sensitive p53 (ts p53) mutation in a subject in need thereof. The method involves first administering to the subject a therapeutically effective amount of a chemotherapeutic drug, then inducing moderate hypothermia in the tumor for a duration sufficient to activate the mutant p53 to enhance the efficacy of the drug.
-
公开(公告)号：WO2022174172A1
公开(公告)日：2022-08-18
申请号：PCT/US2022/016383
申请日：2022-02-15
发明人： DAVILA, Marco L.
摘要： Disclosed herein are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer having endodomains with a customized number of immunoreceptor tyrosine-based activation motifs (ITAMs). In some embodiments, the endodomain has a backbone of a receptor endodomain, such as CD8, CD3ζ, CD3δ, CD3γ, CD3ε, CD32 (Fc gamma RIIa), DAP10, DAP12, CD79a, CD79b, FcγRIγ, FcγRIIIγ, FcεRIβ (FCERIB), and FcεRIγ (FCERIG). In particular embodiments disclosed herein, the backbone is a DAP12 backbone. The disclosed endodomain is engineered to express at least one heterologous ITAM, including 1, 2, 3, 4, 5, or 6 ITAMs.
-
公开(公告)号：WO2022093944A2
公开(公告)日：2022-05-05
申请号：PCT/US2021/056829
申请日：2021-10-27
发明人： BEG, Amer , CANTWELL, Mark J.
IPC分类号： C12N15/86 , A61K35/761 , A61P35/00 , C12N2510/00 , C12N2710/10343 , C12N2740/16043 , C12N5/0638
摘要： Disclosed are and methods for expanding tumor infiltrating lymphocyte (TIL) populations and methods of the use of the expanded TIL population for treating cancer.
-
公开(公告)号：WO2022040628A1
公开(公告)日：2022-02-24
申请号：PCT/US2021/047146
申请日：2021-08-23
IPC分类号： A61K35/15 , A61K35/00 , A61K39/395 , A61K31/337 , A61K35/741
摘要： Disclosed are anti-cancer therapies comprising i) at least one dendritic cell pulsed with an oncodriver and ii) a fecal microbial transplant (FMT) from a pathologic complete response (pCR) donor or a cyclin-dependent kinase (CDK) inhibitor and methods of the use of said therapies to treat cancer.
-
-
-
-
-
-
-
-
-
搜索结果
319 条记录 (耗时 0.035 秒)
